MRNA vs VRTX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 15, 2026

MRNA

38.7
AI Score
VS
VRTX Wins

VRTX

45.0
AI Score

Investment Advisor Scores

MRNA

39score
Recommendation
SELL

VRTX

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA VRTX Winner
Revenue 534.00M 6.32B VRTX
Net Income -2.13B 2.13B VRTX
Net Margin -397.9% 33.7% VRTX
Operating Income -2.20B 2.38B VRTX
ROE -31.4% 10.5% VRTX
ROA -19.4% 7.8% VRTX
Total Assets 10.96B 27.42B VRTX
Cash 1.72B 6.14B VRTX
Current Ratio 2.29 3.19 VRTX
Free Cash Flow -1.25B 2.31B VRTX

Relative Price Performance (Last 90 Days)

MRNA 1M: -11.7% · 3M: +140.8% VRTX 1M: -7.9% · 3M: +12.6%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 63

RSI (14): 63.3 · Price: $154.04

VRTX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 41

RSI (14): 41.4 · Price: $508.34

Fundamentals Snapshot

Metric MRNA VRTX
Market Cap
Forward P/E -32.2 25.3
Trailing P/E 29.8
Revenue (TTM)
Revenue Growth 0.0% 0.1%
Gross Margin -0.7% 0.5%
Operating Margin -5.6% 0.4%
EPS -8.66 17.30
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, VRTX is currently the stronger investment candidate, winning 10 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.